SBIR Phase II: Commercializing Architect-directed DNA Synthesis

The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase II project is to expand innovation in the biotechnology sector through the commercialization of a new DNA (Deoxyribonucleic Acid) synthesis technology. DNA synthesis is a fundamental tool for the life sciences, yet existing methods are limited by high error rates, allowing only for the construction of short strands. Assembling these short segments into the longer sequences required for advanced research is currently a slow, expensive, and labor-intensive process that frequently fails. This project seeks to overcome these barriers by commercializing a novel synthesis platform that significantly reduces costs and production times while enabling the creation of long and complex DNA sequences. The successful deployment of this technology will strengthen the domestic bioeconomy by providing a superior, onshore source for a critical biotechnological resource, enabling researchers to significantly accelerate their development timelines. These advances may have profound commercial impact by fostering the development of new therapeutics, enhancing productivity, and driving growth in biomanufacturing. The proposed project aims to commercialize an automated, enzymatic DNA (Deoxyribonucleic Acid) synthesis platform that utilizes a hierarchical assembly approach. Traditional synthesis relies on single-nucleotide additions that are prone to error; in contrast, this technology employs small double-stranded DNA precursors that are enzymatically assembled in an exponential fashion to create long-form genes. The primary objectives of this Phase II research are to: (i) establish a robust, automated manufacturing line capable of producing multi-kilobase complex genes with integrated sequence quality control; (ii) optimize process stability and reagent handling protocols for enzymes and reaction components to ensure commercial-grade reliability; and (iii) validate the system through the synthesis of varied, complex sequences. Additionally, the project includes research into how enzyme properties impact the fidelity of automated assembly. The anticipated result is a scalable manufacturing process that provides high-fidelity, complex genetic material. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.